Date Insider Type Main position Quantity % Market Cap. Importance
10/23/23 A Free

General Counsel

70,000 0.7479%
10/16/23 A Free

Chief Financial Officer

151,416 1.6178%
9/15/23 A
Versi Group LLC
ConversionCompany 729,200 7.7913%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%-99.00% - - 10
+0.37%-5.96%+30.12%+127.16% 1,204B
+1.51%-4.89%+33.84%+81.30% 643B
+1.53%-2.22%+25.73%+108.58% 501B
-0.59%-2.10%+27.07%+67.07% 378B
+1.87%-8.19%+42.84%+32.11% 327B
+0.11%-4.94%+26.91%+51.21% 285B
+0.96%-3.89%-1.55%+32.97% 270B
+1.13%-5.29%+31.23%+66.20% 237B
+1.39%+0.60%+35.29%+122.49% 207B
Average -9.07%-4.40%+27.94%+76.57% 450B
Weighted average by Cap. +0.86%-4.71%+28.90%+88.87%
Logo DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Employees
12
  1. Stock Market
  2. Stocks
  3. DMKPQ Stock